Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.
Gene protein assay
HER2
Immunohistochemistry
In situ hybridization
Tissue microarray
Whole tissue section
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
15
11
2019
accepted:
04
02
2020
revised:
13
01
2020
pubmed:
23
2
2020
medline:
30
7
2020
entrez:
22
2
2020
Statut:
ppublish
Résumé
Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005-2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.
Identifiants
pubmed: 32080761
doi: 10.1007/s00428-020-02768-x
pii: 10.1007/s00428-020-02768-x
pmc: PMC7371653
doi:
Substances chimiques
Biomarkers, Tumor
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317-320Subventions
Organisme : Cancerfonden
ID : 2017/368
Organisme : Medicinska Fakulteten, Lunds Universitet
ID : NA
Organisme : Fru Berta Kamprads Stiftelse
ID : 2017-4
Organisme : Region Skåne
ID : 40620
Organisme : Skånes universitetssjukhus
ID : NA
Références
Escriva-de-Romani S, Arumi M, Bellet M, Saura C (2018) HER2-positive breast cancer: current and new therapeutic strategies. Breast 39:80–88. https://doi.org/10.1016/j.breast.2018.03.006
doi: 10.1016/j.breast.2018.03.006
pubmed: 29631097
Regionala cancercentrum (2018) Swedish guidelines concerning breast pathology (Kvalitetsdokument för patologi). Available from: http://www.svfp.se/foreningar/uploads/L15178/kvast/brostpatologi/KVASTbrostcancer2018.pdf . Accessed 2019-11-01
Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R (2005) Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 29(11):1505–1511. https://doi.org/10.1097/01.pas.0000172294.67409.4f
doi: 10.1097/01.pas.0000172294.67409.4f
pubmed: 16224218
Varga Z, Tubbs RR, Moch H (2014) Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification. PLoS One 9(8):e105961. https://doi.org/10.1371/journal.pone.0105961
doi: 10.1371/journal.pone.0105961
pubmed: 25153153
pmcid: 4143343
Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E, Grogan TM (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66(6):313–324. https://doi.org/10.1111/pin.12407
doi: 10.1111/pin.12407
pubmed: 27061008
Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H (2017) Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: implications for prognosis in different treatment groups. Oncotarget 8(6):9093–9107. https://doi.org/10.18632/oncotarget.14082
doi: 10.18632/oncotarget.14082
pubmed: 28030849
Fernö M, Haglund M, Bendahl PO, Olsson H, Rydén L (2008) Analys av HER2 i bröstcancer kvalitetssäkrad. Läkartidningen 105(32):32–33
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329. https://doi.org/10.1093/annonc/mdp322
doi: 10.1093/annonc/mdp322
pubmed: 19535820
pmcid: 2720818
Hedner C, Borg D, Nodin B, Karnevi E, Jirström K, Eberhard J (2018) Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. J Clin Pathol 71(5):451–462. https://doi.org/10.1136/jclinpath-2017-204774
doi: 10.1136/jclinpath-2017-204774
pubmed: 29138285
Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C (2016) Tissue microarray is a reliable tool for the evaluation of HER2 amplification in breast cancer. Anticancer Res 36(9):4661–4666. https://doi.org/10.21873/anticanres.11017
doi: 10.21873/anticanres.11017
pubmed: 27630309
Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ (2012) Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res 14(3):R93. https://doi.org/10.1186/bcr3208
doi: 10.1186/bcr3208
pubmed: 22694844
pmcid: 3446356
Ekholm M, Grabau D, Bendahl PO, Bergh J, Elmberger G, Olsson H, Russo L, Viale G, Ferno M (2015) Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. Acta Oncol 54(7):1040–1048. https://doi.org/10.3109/0284186X.2015.1037012
doi: 10.3109/0284186X.2015.1037012
pubmed: 25959664
Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24(19):3032–3038. https://doi.org/10.1200/JCO.2005.03.4744
doi: 10.1200/JCO.2005.03.4744
pubmed: 16809727
Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C (2017) Concordance of HER2 immunohistochemistry and fluorescence in situ hybridization using tissue microarray in breast cancer. Anticancer Res 37(6):3323–3329. https://doi.org/10.21873/anticanres.11701
doi: 10.21873/anticanres.11701
pubmed: 28551685
Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, Ambrosone CB, Olshan AF, Troester MA (2016) Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Res 18(1):68. https://doi.org/10.1186/s13058-016-0725-1
doi: 10.1186/s13058-016-0725-1
pubmed: 27349894
pmcid: 4924300
Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW (2012) Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer 118(4):914–923. https://doi.org/10.1002/cncr.26406
doi: 10.1002/cncr.26406
pubmed: 21800290